<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1561-3194</journal-id>
<journal-title><![CDATA[Revista de Ciencias Médicas de Pinar del Río]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Ciencias Médicas]]></abbrev-journal-title>
<issn>1561-3194</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1561-31942023000700034</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Rol del hiperaldosteronismo primario para el desarrollo de hipertensión arterial]]></article-title>
<article-title xml:lang="en"><![CDATA[Role of primary hyperaldosteronism in the development of arterial hypertension]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Altamirano-Guerrero]]></surname>
<given-names><![CDATA[Olivia Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Barrionuevo]]></surname>
<given-names><![CDATA[Carlos Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salazar-Pullutacsi]]></surname>
<given-names><![CDATA[Karen Daniela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Regional Autónoma de Los Andes  ]]></institution>
<addr-line><![CDATA[Ambato ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>27</volume>
<numero>6</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1561-31942023000700034&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1561-31942023000700034&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1561-31942023000700034&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  el hiperaldosteronismo primario se considera la forma endocrina secundaria más frecuente de hipertensión arterial; se caracteriza por una elevación inadecuada de aldosterona debido a una producción autónoma e independiente del sistema renina-angiotensina-aldosterona.  Objetivo:  describir el rol del hiperaldosteronismo primario en el desarrollo de hipertensión arterial.  Métodos:  se realizó una búsqueda de información en las bases de datos PubMed/MedLine, Scopus y SciELO. Se estructuró una estrategia de búsqueda empleando los términos hipertensión he hiperaldosteronismo.  Resultados:  el hiperaldosteronismo primario es una entidad considerada como la primera causa de hipertensión arterial secundaria, sin embargo, está subdiagnosticada debido al poco conocimiento que se tiene ocasionando que un gran número de pacientes con HTA presenten una resistencia al tratamiento habitual, produciendo un aumento del riesgo cardiovascular, metabólico, renal y cerebrovascular en el paciente.  Conclusiones:  es de gran importante el tamizaje del paciente hipertenso, para una detección del hiperaldosteronismo primario de manera oportuna y su laterización, pues permite guiar un tratamiento adecuado, ya sea farmacológico o quirúrgico, para garantizar la disminución o control de la presión, del riesgo cardiovascular y renal y de la aparición de diabetes mellitus en el paciente para mejorar su calidad de vida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  primary hyperaldosteronism is considered the most frequent secondary endocrine form of arterial hypertension; it is characterized by an inadequate elevation of aldosterone due to an autonomous and independent production of the renin-angiotensin-aldosterone system.  Objective:  to describe the role of primary hyperaldosteronism in the development of arterial hypertension.  Methods:  a search for information was carried out in the PubMed/MedLine, Scopus and SciELO databases. A search strategy was structured using the terms hypertension and hyperaldosteronism.  Results:  primary hyperaldosteronism is an entity considered as the first cause of secondary arterial hypertension; however, it is underdiagnosed due to the lack of knowledge, causing a large number of patients with hypertension to present resistance to the usual treatment, producing an increase in cardiovascular, metabolic, renal and cerebrovascular risk in the patient.  Conclusions:  screening of the hypertensive patient is of great importance for the timely detection of primary hyperaldosteronism and its laterization, since it allows guiding an adequate treatment, either pharmacological or surgical, to guarantee the reduction or control of blood pressure, cardiovascular and renal risk and the appearance of diabetes mellitus in the patient in order to improve his quality of life.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[HIPERTENSIÓN]]></kwd>
<kwd lng="es"><![CDATA[ALDOSTERONA]]></kwd>
<kwd lng="es"><![CDATA[HIPERALDOSTERONISMO]]></kwd>
<kwd lng="en"><![CDATA[HYPERTENSION]]></kwd>
<kwd lng="en"><![CDATA[ALDOSTERONE]]></kwd>
<kwd lng="en"><![CDATA[HYPERALDOSTERONISM]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parra Ramírez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Martín Rojas-Marcos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cuesta Hernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Sánchez]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Lamas Oliveira]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hanzu]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primera encuesta sobre el diagnóstico y tratamiento del hiperaldosteronismo primario por especialistas españoles en Endocrinología y Nutrición]]></article-title>
<source><![CDATA[Endocrinol Diabetes y Nutr]]></source>
<year>2023</year>
<volume>70</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>374-80.</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
<name>
<surname><![CDATA[Elaraj]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation and Management of Primary Hyperaldosteronism]]></article-title>
<source><![CDATA[Surg Clin North Am]]></source>
<year>2019</year>
<volume>99</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>731-45</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ribas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chillarón]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vázquez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carrera]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Ruiz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Galcerán]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Indicación, realización y resultado del cateterismo de venas adrenales en pacientes con hiperaldosteronismo primario.]]></article-title>
<source><![CDATA[Nefrología]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaidya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carey]]></surname>
<given-names><![CDATA[RM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolution of the Primary Aldosteronism Syndrome: Updating the Approach]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2020</year>
<volume>105</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3771-83</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reincke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bancos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mulatero]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Scholl]]></surname>
<given-names><![CDATA[UI]]></given-names>
</name>
<name>
<surname><![CDATA[Stowasser]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of primary aldosteronism]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2021</year>
<volume>9</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>876-92</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vélez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vélez Páez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Aguayo Moscoso]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Navarrete Aráuz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tercero Martínez]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[López Rondón]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endocrinología crítica de las glándulas suprarrenales y el eje hipotálamo hipofisario adrenal.]]></article-title>
<source><![CDATA[Rev Cien Ecu]]></source>
<year>2019</year>
<volume>1</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monge]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Echeverri Lohrengel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Leiva Rojas]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Soto Rivera]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Salas Fernandez]]></surname>
<given-names><![CDATA[MJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fisiopatología y presentación clínica del hiperaldosteronismo primario.]]></article-title>
<source><![CDATA[Rev Cienc y Salud Integr Conoc]]></source>
<year>2021</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Asmar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rajpal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arafah]]></surname>
<given-names><![CDATA[BM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary Hyperaldosteronism]]></article-title>
<source><![CDATA[Med Clin North Am]]></source>
<year>2021</year>
<volume>105</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1065-80.</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adenoma suprarenal productor de aldosterona: reporte de un caso de hiperaldosteronismo primario]]></article-title>
<source><![CDATA[Rev Médico Científica]]></source>
<year>2020</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mulatero]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Monticone]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Deinum]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Amar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Prejbisz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zennaro]]></surname>
<given-names><![CDATA[M-C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2020</year>
<volume>38</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1919-28</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hundemer]]></surname>
<given-names><![CDATA[GL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism]]></article-title>
<source><![CDATA[Front Endocrinol (Lausanne)]]></source>
<year>2022</year>
<volume>13</volume>
<numero>2022</numero>
<issue>2022</issue>
<page-range>861581</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and treatment of primary aldosteronism: practical clinical perspectives]]></article-title>
<source><![CDATA[J Intern Med]]></source>
<year>2019</year>
<volume>285</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>126-48.</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdivia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mora]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Genskowsky]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Novik]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consideraciones diagnósticas actuales sobre el hiperaldosteronismo primario]]></article-title>
<source><![CDATA[Bol Hosp Viña del Mar]]></source>
<year>2020</year>
<volume>76</volume>
<numero>2-3</numero>
<issue>2-3</issue>
<page-range>72-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zennaro]]></surname>
<given-names><![CDATA[M-C]]></given-names>
</name>
<name>
<surname><![CDATA[Boulkroun]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandes-Rosa]]></surname>
<given-names><![CDATA[FL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenesis and treatment of primary aldosteronism]]></article-title>
<source><![CDATA[Nat Rev Endocrinol]]></source>
<year>2020</year>
<volume>16</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>578-89</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Araujo-Castro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bengoa Rojano]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Argüeso]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pascual-Corrales]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez Mendiguchía]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[García Cano]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Riesgo cardiometabólico en pacientes con hiperaldosteronismo primario y secreción autónoma de cortisol. Estudio de casos y controles]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2021</year>
<volume>157</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>473-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
